Supplemental Table 5: Anti-lipid-specific rates and relative hazard ratios of all-cause and cardiovascular mortality by mean low-density lipoprotein cholesterol percentile (<10th, 10th - 25th, 25th - 50th, 50th - 75th, 75th - 90th, >90th) in patients with type 2 diabetes

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mean LDL-C  (mg/dL)1 | Mortality | | |  | Model 1  Adjusted HR (95% CI) 3 |  | Model 2  Adjusted HR (95% CI) 3 |  | Model 3  Adjusted HR (95% CI) 3 |
| No. of patients | No. of mortality | Rates (per 1,000 patient-years)  (95% CI) 2 |  |  |  |
| **All-cause Mortality**  **Statin use only** |  |  |  |  |  |  |  |  |  |
| ≤77 | 1,591 | 398 | 44.25 (39.91-48.60) |  | 1.97 (1.74-2.22)4 |  | 2.01 (1.78-2.27)5 |  | 1.76 (1.52-2.03)6 |
| >77-90 | 3,071 | 527 | 24.63 (22.53-26.73) |  | 1.16 (1.04-1.30)4 |  | 1.17 (1.05-1.30)5 |  | 1.17 (1.03-1.32)6 |
| >90-103.59 | 5,589 | 829 | 20.20 (18.83-21.58) |  | 1.00 (Reference) |  | 1.00 (Reference) |  | 1.00 (Reference) |
| >103.59-119 | 5,639 | 944 | 24.18 (22.63-25.72) |  | 1.29 (1.18-1.42)4 |  | 1.32 (1.21-1.45)5 |  | 1.09 (0.98-1.21)6 |
| >119-135.5 | 3,264 | 680 | 34.17 (31.60-36.74) |  | 1.84 (1.67-2.04)4 |  | 1.90 (1.72-2.11)5 |  | 1.21 (1.07-1.38)6 |
| >135.59 | 2,473 | 694 | 55.82 (51.66-59.97) |  | 3.61 (3.26-4.00)4 |  | 3.66 (3.31-4.05)5 |  | 1.37 (1.17-1.60)6 |
| **Fribrates use only** |  |  |  |  |  |  |  |  |  |
| ≤77 | 384 | 159 | 58.75 (49.62-67.88) |  | 1.38 (1.11-1.72)4 |  | 1.31 (1.05-1.64)5 |  | 1.41 (1.04-1.90)6 |
| >77-90 | 394 | 115 | 39.77 (32.50-47.04) |  | 1.02 (0.80-1.30)4 |  | 0.99 (0.78-1.26)5 |  | 1.10 (0.82-1.48)6 |
| >90-103.59 | 480 | 164 | 46.18 (39.11-53.25) |  | 1.00 (Reference) |  | 1.00 (Reference) |  | 1.00 (Reference) |
| >103.59-119 | 446 | 142 | 46.76 (39.06-54.45) |  | 1.19 (0.95-1.49)4 |  | 1.19 (0.95-1.50)5 |  | 1.17 (0.88-1.55)6 |
| >119-135.5 | 228 | 77 | 64.09 (49.77-78.40) |  | 2.09 (1.59-2.75)4 |  | 2.26 (1.72-2.98)5 |  | 2.24 (1.56-3.20)6 |
| >135.59 | 127 | 59 | 89.85 (66.93-112.78) |  | 2.95 (2.18-3.99)4 |  | 2.91 (2.15-3.94)5 |  | 1.36 (0.87-2.13)6 |
| **Cardiovascular Mortality**  **Statin use only** |  |  |  |  |  |  |  |  |  |
| ≤77 | 1,591 | 104 | 11.56 (9.34-13.79) |  | 2.60 (2.03-3.32)4 |  | 2.61 (2.04-3.34)5 |  | 2.17 (1.62-2.92)6 |
| >77-90 | 3,071 | 116 | 5.42 (4.44-6.41) |  | 1.30 (1.02-1.65)4 |  | 1.29 (1.02-1.64)5 |  | 1.31 (1.00-1.72)6 |
| >90-103.59 | 5,589 | 164 | 4.00 (3.39-4.61) |  | 1.00 (Reference) |  | 1.00 (Reference) |  | 1.00 (Reference) |
| >103.59-119 | 5,639 | 200 | 5.12 (4.41-5.83) |  | 1.38 (1.12-1.70)4 |  | 1.41 (1.15-1.74)5 |  | 1.23 (0.97-1.56)6 |
| >119-135.5 | 3,264 | 158 | 7.94 (6.70-9.18) |  | 2.18 (1.75-2.71)4 |  | 2.25 (1.81-2.80)5 |  | 1.60 (1.22-2.10)6 |
| >135.59 | 2,473 | 152 | 12.23 (10.28-14.17) |  | 3.99 (3.20-4.98)4 |  | 4.10 (3.28-5.12)5 |  | 1.69 (1.21-2.37)6 |
| **Fibrates use only** |  |  |  |  |  |  |  |  |  |
| ≤77 | 384 | 24 | 8.87 (5.32-12.42) |  | 1.13 (0.67-1.93)4 |  | 1.11 (0.65-1.91)5 |  | 1.19 (0.55-2.60)6 |
| >77-90 | 394 | 17 | 5.88 (3.09-8.67) |  | 0.82 (0.46-1.49)4 |  | 0.81 (0.45-1.47)5 |  | 1.34 (0.68-2.66)6 |
| >90-103.59 | 480 | 32 | 9.01 (5.89-12.13) |  | 1.00 (Reference) |  | 1.00 (Reference) |  | 1.00 (Reference) |
| >103.59-119 | 446 | 27 | 8.89 (5.54-12.24) |  | 1.20 (0.71-2.02)4 |  | 1.25 (0.74-2.10)5 |  | 1.30 (0.66-2.58)6 |
| >119-135.5 | 228 | 18 | 14.98 (8.06-21.90) |  | 2.75 (1.52-4.96)4 |  | 2.93 (1.62-5.32)5 |  | 4.25 (1.95-9.29)6 |
| >135.59 | 127 | 10 | 15.23 (5.79-24.67) |  | 2.89 (1.41-5.93)4 |  | 2.95 (1.43-6.09)5 |  | 1.67 (0.48-5.82)6 |

1 LDL-C: low-density cholesterol

2 Based on Poisson assumption, CI=confidence interval

3 HR= hazard ratio; CI=confidence interval

4 Based on Cox proportional hazard regression adjusting for general characteristics (i.e., age, and sex)

5 Based on Cox proportional hazard regression adjusting for the general characteristics in Model 1 plus the antidiabetic, antihypertensive, and antilipid medications presented in Table 1.

6 Based on Cox proportional hazard regression with all covariates included in Model 2 plus comorbidities, complications, and laboratory results presented in Table 1.

*P* values for the interaction of mean LDL-C with statins and fibrates were 0.02655 and 0.7129, respectively.